ACRO BIOMEDICAL CEO Resigns; Board Appoints New CEO & Chairman

What Happened
ACRO BIOMEDICAL Co., Ltd. filed an 8-K on September 2, 2026 (Item 5.02) announcing that Yu‑Ting Su resigned as director, chairman and chief executive officer effective upon the appointment of a successor. The board appointed Shao‑Hsiang Shih as director and chairman and Jing‑Zhou (Nick) Chen as chief executive officer and chief financial officer, all effective September 2, 2026. The filing states Ms. Su’s resignation was not due to any disagreement with the company.

Key Details

• Resignation and appointments disclosed in an 8-K filed September 2, 2026 (Item 5.02).
• Yu‑Ting Su resigned as director, chairman and CEO effective upon successor appointment; resignation not due to disagreement.
• Shao‑Hsiang Shih appointed director and chairman effective September 2, 2026; background: Director of Administrative Management at Century Publishing Co. (since 2020); prior roles at Century Publishing Co. and Century Education Center; B.S. in Statistics (National Taipei University, 2003); M.A. (Fo Guang University, 2018); doctoral studies at Huafan University (since 2018).
• Jing‑Zhou (Nick) Chen appointed CEO and CFO effective September 2, 2026; background: CEO/founder of Dream Born Co., Ltd. (since March 2025), prior CEO of GBT Cloud Kitchen / Hongxi Enterprise Management (2020–2025), other roles in operations and semiconductor engineering; B.S. in Electrical Engineering (National United University, 2010); currently enrolled in an Executive MBA program.

Why It Matters
Leadership changes at the CEO and chairman level are material events investors monitor because they can affect company strategy, governance and execution. The filing confirms a planned transition (resignation upon successor appointment) and provides the new leaders’ professional backgrounds—useful for assessing experience in operations, technology and management. Investors may want to watch forthcoming communications from ACRO BIOMEDICAL about any strategic or operational updates under the new leadership.